Seeking Alpha

- Precisely sized, bioresorbable gelatin beads intended for embolization of hypervascular tumors

- Designed for use by interventional radiologists who currently use microspheres, PVA particles, and gelatin foam slurries

- Offers physicians a new treatment option when a permanent embolic agent is not desired

MINNEAPOLIS, June 19, 2014 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (VASC) today announced the U.S. market launch of its Gel-Bead embolization spheres for the treatment of hypervascular tumors.

Gel-Bead embolization spheres are precisely sized, bioresorbable beads of gelatin that are absorbed by the body over time, providing physicians with a treatment option for hypervascular tumors in cases when a permanent embolic agent is not desired. Gel-Bead, which received 510(k) clearance from the U.S. Food and Drug Administration in April, will be sold to interventional radiologists who currently embolize hypervascular tumors with microspheres, PVA particles, and gelatin foam slurries.

"We are very pleased to announce the launch of Gel-Bead, our latest offering to leverage our biologics expertise in the field of embolization," said Howard Root, Chief Executive Officer of Vascular Solutions. "Our first vascular embolization product, Gel-Block, consists of a pledget of gelatin foam that is radially compressed for superior delivery and was launched in July 2012. Now, with the launch of Gel-Bead, we offer the additional configuration of uniform spheres designed for smooth embolic delivery and predictable distribution, all at a very economical price. Over time, we plan to continue to add to our embolization products with future versions designed to meet specific therapeutic needs."

Gel-Bead is supplied in 20ml syringes, each containing 1ml of gelatin spheres suspended in 5ml of saline. Gel-Bead is available in four sizes of sphere diameter (100-300 microns, 300-500 microns, 500-700 microns, and 700-1,000 microns), each identified by a different colored syringe plunger.

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of more than 80 products in three categories: catheter products, hemostat products and vein products. Vascular Solutions delivers its products to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.

The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2013 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, lack of sustained profitability, exposure to intellectual property claims, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, doing business in international markets, the availability of third party reimbursement, and actions by the FDA.

For further information, connect to www.vasc.com .

CONTACT: Vascular Solutions, Inc.
         Phil Nalbone, VP-Corp. Dev.
         PNalbone@vasc.com
         (763) 656-4371
Source: Vascular Solutions, Inc. 2014 GlobeNewswire, Inc.
Comments (0)
Be the first to comment